Search Within

David H Ilson

  1. "Computational Oncology Service"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (13)
Groups
  1. Computational Oncology Service (30)
  2. Department of Medicine (30)
  3. Epidemiology and Biostatistics (30)
  4. GSK Faculty (30)
  5. Gastrointestinal Oncology Service (30)
  6. Hematologic Malignancies, Division of (30)

More Groups

People
  1. Geoffrey Ku (30)
  2. Nikolaus Schultz (30)
  3. Yelena Janjigian (30)
  4. David Solit (21)
  5. Jaclyn Hechtman (19)
  6. David Kelsen (18)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (4)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Clinical Cancer Research (4)
  3. Annals of Oncology (2)
  4. Cancer Discovery (2)
  5. JAMA Network Open (2)
  6. Annals of Surgery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. American Association for Cancer Research (6)
  3. Oxford University Press (4)
  4. American Medical Association (2)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer
    Journal Article

    Ku, G. Y.; Kemel, Y.; Maron, S. B.; Chou, J. F.; Ravichandran, V.; Shameer, Z.; Maio, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer
    Journal Article

    Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy
    Meeting Abstract

    Greally, M.; Walch, H. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Schultz, N.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
    Journal Article

    Greally, M.; Chou, J. F.; Chatila, W. K.; Margolis, M.; Capanu, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Daian, F.; Ladanyi, M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save